non-small-cell lung cancer
Conditions
Interventions
Intervention Group (Phase 1):Cryoablation
Intervention Group (Phase 2):Cryoablation
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. >= 18 years old; 2. PS <=2; 3. Histopathological confirmation of NSCLC (lung adenocarcinoma or lung squamous cell carcinoma); 4. Participants who develop tumor progression (PD) after at least 2 cycles of first-line or second-line immunotherapy resistance, using immune checkpoint inhibitors +/- chemotherapy and other treatment regimens; 5. Local progression or oligometastasis; 6. Expected lifespan greater than 6 months.
Exclusion criteria
Exclusion criteria: 1. Participants with brain metastases; 2. Merge participants with other tumors; 3. Participants who have previously undergone cryoablation therapy; 4. Participants with extensive metastasis after immunotherapy (>2 metastatic sites, >= 5 metastatic lesions); 5. Participants who are not suitable for cryoablation due to infection, uncorrectable bleeding risk, and other reasons; 6. Participants participating in other clinical trials; 7. EGFR/ALK positive participants; 8. Participants with immune therapy intolerance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-month disease control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 6-month disease control rate;6-month objective response rate;6-month progression free survival rate; | — |
Countries
China
Contacts
Public ContactPanwen Tian
West China Hospital, Sichuan University
Outcome results
None listed